189 related articles for article (PubMed ID: 7559734)
21. [Correlation of the levels of the bone turnover markers BAP and β-CTX with bone metastasis progress in lung cancer patients].
Tang Q; Zhao H; Jia R; Liu L
Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):144-7. PubMed ID: 23514943
[TBL] [Abstract][Full Text] [Related]
22. Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer.
Kong D; Ye C; Zhang C; Sun X; Wang F; Chen R; Xiao G; He S; Xu J; Rao X; Ai J; Gao X; Li H; Su L
J Exp Clin Cancer Res; 2023 Feb; 42(1):45. PubMed ID: 36759880
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
Keller ET; Brown J
J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
[TBL] [Abstract][Full Text] [Related]
24. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
[TBL] [Abstract][Full Text] [Related]
25. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M
Respirology; 2005 Jun; 10(3):300-4. PubMed ID: 15955141
[TBL] [Abstract][Full Text] [Related]
26. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A.
Hashimoto K; Ochi H; Sunamura S; Kosaka N; Mabuchi Y; Fukuda T; Yao K; Kanda H; Ae K; Okawa A; Akazawa C; Ochiya T; Futakuchi M; Takeda S; Sato S
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):2204-2209. PubMed ID: 29440427
[TBL] [Abstract][Full Text] [Related]
27. MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D
Anticancer Res; 2017 Mar; 37(3):1501-1505. PubMed ID: 28314325
[TBL] [Abstract][Full Text] [Related]
28. Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis.
Jung K; Lein M
Biochim Biophys Acta; 2014 Dec; 1846(2):425-38. PubMed ID: 25220832
[TBL] [Abstract][Full Text] [Related]
29. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
30. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
Chirgwin JM; Guise TA
Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
[TBL] [Abstract][Full Text] [Related]
32. Serum concentration of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with metastatic breast cancer.
Maemura M; Iino Y; Yokoe T; Takei H; Horiguchi J; Koibuchi Y; Ikeda F; Ohwada S; Takeyoshi I; Morishita Y
Oncol Rep; 2000; 7(6):1333-8. PubMed ID: 11032939
[TBL] [Abstract][Full Text] [Related]
33. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.
Feeley BT; Liu NQ; Conduah AH; Krenek L; Roth K; Dougall WC; Huard J; Dubinett S; Lieberman JR
J Bone Miner Res; 2006 Oct; 21(10):1571-80. PubMed ID: 16995812
[TBL] [Abstract][Full Text] [Related]
34. Orthopedic surgery implications of breast cancer.
Marulanda GA; Mont MA; Lucci A; Letson GD; Khakpour N
Expert Rev Anticancer Ther; 2008 Jun; 8(6):949-56. PubMed ID: 18533804
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of osteolytic bone metastases in breast carcinoma.
Käkönen SM; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):834-9. PubMed ID: 12548583
[TBL] [Abstract][Full Text] [Related]
36. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
[TBL] [Abstract][Full Text] [Related]
37. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
38. [
Janssen JC; Woythal N; Meißner S; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
Mol Imaging Biol; 2017 Dec; 19(6):933-943. PubMed ID: 28707038
[TBL] [Abstract][Full Text] [Related]
39. Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane.
Martinetti A; Bajetta E; Seregni E; Zilembo N; Ferrari L; Noberasco C; Massaron S; Rimassa L; Bombardieri E
Tumour Biol; 1997; 18(4):197-205. PubMed ID: 9218004
[TBL] [Abstract][Full Text] [Related]
40. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
